Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Licenses Targets Resulting from Galapagos Collaboration

NEW YORK, Jan. 20 (GenomeWeb News) - Boehringer Ingelheim has licensed a number of potential antiviral targets from Galapagos Genomics after identifying them using Galapagos' gene knock-down technology, Galapagos said yesterday.

 

Scientists at Boehringer's virology research center in Laval, Canada, used Galapagos' SilenceSelect platform, a collection of adenoviruses with siRNA knock-down sequences targeting over 3,000 human transcripts, to identify a number of genes that influence viral replication in human cells.

 

As part of the two companies' technology agreement from October 2003, Galapagos, which is based in the Netherlandsand Belgium, will obtain a milestone payment from Boehringer for licensing the targets.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.